Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.
The following valpromide (VPD) analogues were synthesized and their structure-pharmacokinetic relationships explored: 3-ethyl pentanamide (EPD), methylneopentylacetamide (MND), 1-methyl cyclohexanecarboxamide (MCD), cycloheptanecarboxamide (CHD), and t-butylacetamide (TBD). Two aliphatic (EPD and MND) and two cyclic amides (MCD and CHD) underwent complete or partial conversion to their corresponding acids. The only amide found in this study to be "stable" to the amide-acid biotransformation was TBD. It also had the lowest clearance and the longest half-life and mean residence time. Unlike the other investigated amides, TBD contained two substitutions of two methyl moieties at the beta position of its chemical structure. A "stable" valpromide analogue must have either two substitutions at the beta position, such as in the case of TBD, or a substitution in the alpha and beta positions, such as in the case of the VPD isomer valnoctamide (VCD). This paper discusses the antiepileptic potential of stable VPD analogues which may be more potent and less teratogenic than their biotransformed isomers.
Haj-Yehia
A
A
Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel.
Hadad
S
S
Bialer
M
M
D000818:Animals; D001711:Biotransformation; D002849:Chromatography, Gas; D004285:Dogs; D005260:Female; D006207:Half-Life; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D011485:Protein Binding; D012995:Solubility; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014635:Valproic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics
D014635:Valproic Acid; C004651:dipropylacetamide